ARTICLE | Translation in Brief
No problem, Houston
EMD Serono taps MD Anderson's APOLLO platform for high-standard biopsy studies
February 23, 2017 6:54 PM UTC
EMD Serono is betting MD Anderson's patient monitoring platform, which integrates longitudinal biopsy data with medical histories, will provide a clear view of biological responses and biomarkers for its Phase I cancer compounds by avoiding common pitfalls in molecular profiling.
The three-year collaboration's January launch makes the EMD Serono unit of Merck KGaA (Xetra:MRK) the first company to access the platform, but the University of Texas MD Anderson Cancer Center believes more could follow...